Baggio 1994b.

Methods	4‐week single‐blind placebo washout period 6‐week before and after trial
Participants	39 men and women with type IIA primary hypercholesterolaemia mean age 67 years LDL‐cholesterol ≥ 160 mg/dL ( ≥ 4.14 mmol/L) triglycerides ≤ 250 mg/dL (≤ 2.82 mmol/L) exclusion criteria: secondary dyslipidaemia, diabetes mellitus controlled with drugs, obesity BMI ≥29 abnormal liver and renal function, cancer, MI and coronary bypass surgery Fluvastatin 40 mg/day baseline TC : 8.17 mmol/L (316 mg/dL) Fluvastatin 40 mg/day baseline LDL‐C : 5.92 mmol/L (229 mg/dL) Fluvastatin 40 mg/day baseline HDL‐C : 1.5 mmol/L (58 mg/dL Fluvastatin 40 mg/day baseline triglycerides: 1.64 mmol/L (145 mg/dL)
Interventions	Fluvastatin 40 mg/day
Outcomes	per cent change from baseline at 3‐6 weeks of serum TC, LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	High risk	15.4% participants were not included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding not reported